Improving Maternal Mental Health & SUD Screening and Treatment
Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Mar 1, 2023
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Aim 1: To determine differences in rates of treatment attendance and retention for Perinatal Mood and Anxiety Disorders (PMADs) and Perinatal Substance Use Disorders (PSUDs) between participants assigned to LTWP, compared to SBIRT.
Aim 2: To determine differences in Patient-Reported Outcomes (PROs) including depressive symptoms, quality of life, substance use, and maternal functioning and well-being measured at baseline and 2, 5, 8, and 11 months postpartum.
Gender
FEMALE
Eligibility criteria
- Aim 1:
- • This study is a cluster RCT step wedge design so we are randomizing on the clinic level, not the individual level. The clinics are made up of 4 "wedges" (3 clinics/wedge). Pregnant women receiving prenatal care in these clinics will receive SBIRT as part of usual care. Clusters of clinics will be randomized to an LTWP start date where they will transition from SBIRT to LTWP for the purposes of screening and referral to treatment.
- EHR Data Collection (PPP):
- Inclusion:
- • 1. Age 18-45
- • 2. pregnant and entering prenatal care in one of MUSC's OB clinics
- • 3. attended a prenatal appointment at an MUSC clinic
- Exclusion:
- • a.) primary language is not English or Spanish
- Aim 2:
- Study Assessments at baseline and 2, 5, 8, and 11 months postpartum (PPP):
- Inclusion:
- • 1. Age 18-45 years
- • 2. pregnant
- • 3. attended an initial prenatal appointment at an MUSC OB clinic
- Exclusion:
- • 1. Unable to complete study assessments
- • 2. primary language is not English or Spanish
About Medical University Of South Carolina
The Medical University of South Carolina (MUSC) is a leading academic health center dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on translational medicine, MUSC leverages its extensive resources and expertise to facilitate groundbreaking studies across various medical disciplines. The institution is committed to fostering collaboration among researchers, healthcare professionals, and patients, ensuring that cutting-edge discoveries translate into effective treatments. As a pioneer in health education and research, MUSC plays a vital role in shaping the future of medicine and enhancing health outcomes in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charleston, South Carolina, United States
Patients applied
Trial Officials
Constance Guille, MD
Principal Investigator
Medical University of South Carolina
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials